Genmab AS Quote - GE9

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

197.30

Bid

195.60

Ask

197.55

Volume

124

195.35 Day's Range 197.80

191.95 52 Week Range 305.20

Market Cap

12.961B

Previous Close

196.20

Open

196.55

Last Trade

197.3

Last Trade Time

11:26:13

Financial Volume

VWAP

Average Volume (3m)

310

Shares Outstanding

65,691,573

Dividend Yield

PE Ratio

3.06

Earnings Per Share (EPS)

66.25

Revenue

16.47B

Net Profit

4.35B

Sector

Biological Pds,ex Diagnstics

Industry

Biogenetic (human)

Website

www.genmab.com

Headquarters

Copenhagen, Dnk

Founded

2000

Genmab AS is listed in the Biological Pds,ex Diagnstics sector of the Tradegate (DE) with ticker GE9. The last closing price for Genmab AS was 196.20 €. Over the last year, Genmab AS shares have traded in a share price range of 191.95 € to 305.20 €.

Genmab AS currently has 65,691,573 shares outstanding. The market capitalization of Genmab AS is 12.89 € billion. Genmab AS has a price to earnings ratio (PE ratio) of 3.06.

Genmab to Present at Citi’s Global Healthcare Conference

Genmab to Present at Citi’s Global Healthcare Conference Media ReleaseCOPENHAGEN, Denmark; November 25, 2024 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony...

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; November 21, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided...

Genmab Announces Financial Results for the First Nine Months of 2024

Genmab Announces Financial Results for the First Nine Months of 2024 November 6, 2024 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2024 Highlights European...

Genmab to Present at Jefferies London Healthcare Conference

Genmab to Present at Jefferies London Healthcare Conference Media ReleaseCOPENHAGEN, Denmark; November 5, 2024 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer, Jan van...

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting Media ReleaseCOPENHAGEN, Denmark; November...

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024 Company Announcement Net sales of DARZALEX® in the third quarter of 2024 totaled USD 3,016 millionGenmab receives...

Major Shareholder Announcement

Major Shareholder Announcement Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; October 4, 2024 – Genmab A/S (Nasdaq: GMAB) announces under reference to...

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; September 26, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided...

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial...

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; September 10, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	2.45	1.25737746985	194.85	200.7	191.95	284	196.72417195	DE
4	-16.5	-7.7174929841	213.8	220.8	191.95	382	205.72247905	DE
12	-53.7	-21.3944223108	251	253.5	191.95	310	214.98863343	DE
26	-60.8	-23.5567609454	258.1	269.5	191.95	258	228.56106715	DE
52	-91.5	-31.6828254848	288.8	305.2	191.95	212	245.00665577	DE
156	-154.9	-43.9806927882	352.2	362.9	191.95	157	251.58008515	DE
260	-176.3	-47.1895074946	373.6	374.3	191.95	155	251.58996865	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
2RZPoseida Therapeutics Inc	8.81 € (222.47%)	46.57k
GMEGeratherm Medic	5.55 € (83.77%)	91.55k
7S2Scotch Creek Ventures Inc	0.0144 € (67.44%)	100k
AXIAtos SE	0.62 € (64.24%)	2.87M
ZN80Hesai Group	7.20 € (59.29%)	37.64k
CHPCitigold Corporation Ltd	0.001 € (-60.00%)	250k
L7C2Windfall Geotek Inc	0.0025 € (-54.55%)	500
QN90Military Metals Corp	0.262 € (-40.18%)	302.46k
0Z2Alector Inc	2.44 € (-35.45%)	17.64k
PKTMPIERER Mobility AG	9.20 € (-34.75%)	169.7k
R1EAEV Resources Ltd	0.002 € (25.00%)	4.8M
D7GNel ASA	0.2708 € (0.67%)	3.08M
PF8European Lithium Limited	0.0168 € (0.00%)	2.96M
AXIAtos SE	0.62 € (64.24%)	2.87M
3CPXiaomi Corporation	3.3085 € (-4.68%)	2.05M

learningcurve2020 4 minutes ago

dstuck needs a new chair.

https://www.flickr.com/photos/26686573@N00/2072880506

NWBO

arizona1 4 minutes ago

Kennedy is going to be in charge of this. What could possibly go wrong?

https://substackcdn.com/image/fetch/w_470,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Faa6e0279-c8af-4a06-9b63-475b4ebf1044_470x465.png

jdcpa1 5 minutes ago

Oh so now OTC is giving opinions as yiu suggest? That's the complete opposite of what you said yesterday. Notice the internal conflict? Lol

Get a grip dude, you cant have it both ways.. clown..

SPZI

qualityincolor 5 minutes ago

They gave me 10k on 9s at 12:01 and nothing since. Give em

RDAR

Hoskuld 5 minutes ago

Doesn't know what ADL is or how it is measured...isn't familiar with ADAS-Cog13 standards. Sure, he recognized SAVA would fail but many of us have been saying that since their 3rd OL data release ~2 years ago (or since Wang was indicted or since CEO and CSO were forced out under threat of indictmen

AVXL

Adiamed 5 minutes ago

Don't believe everything you read! The case was settled 15 years ago. There was no fraud and no conviction.
Most people will never understand the politics in that case, and you will never find the truth online.

Let me ask you this.
If you were told you would be in a whee

ADIA

sab63090 6 minutes ago

Just my opinion:

The selling is "programmed" by the mm's helping out the hedge funds and so far the line in the sand has been attacked successfully by this cooperation/collusion and has disrupted what might have been a painful advance for them...

I thought the longs w

AVXL

Zorax 7 minutes ago

Meanwhile 85% of their ratings is 1 out of 5, but hey you know better lol. 85% of the ratings are by scam ceo's covering up like uhf does. lol.

RGLG

glenn1919 7 minutes ago

IVDA..................https://stockcharts.com/h-sc/ui?s=IVDA&p=W&b=5&g=0&id=p86431144783

IVDA

IrishBayou 7 minutes ago

I believed Bob Wilder many years ago. I am in jail and cannot pass GO. By the time I started following your postings it was toooooo late.

VTXB

IrishBayou 7 minutes ago

I believed Bob Wilder many years ago. I am in jail and cannot pass GO. By the time I started following your postings it was toooooo late.

VTXB

LOVELWLG 7 minutes ago

The push back to 2025 and their track record could mean December 2025. Stock will definately explore new lows for sure with no news to support it.

LWLG

ubueltp 7 minutes ago

Yaa and the stock was struggling and diluting for 7-9 years and thought it was dead money. Always respected the ceo who owns about 25-30% of the stock and more held by insiders. A lot changed in the last 2 years. I caught up a year or so. Gee let’s see if there’s an opinion on my other stock. Again,

MPW

koolmc 7 minutes ago

:) or do chores that you have been putting off like putting up the christmas lights lol

grantastic 8 minutes ago

Should people even trust the published financials are accurate?

https://x.com/CarlLedowski/status/1861245844852183082

$APRU

APRU

archilles 8 minutes ago

Sounded like you sold today. How many shares did you sell today?

FMCC

Monksdream 8 minutes ago

PDYN again

PDYN

Guido2 9 minutes ago

https://x.com/GuidoPerei/status/1861500911400690136

FNMA

resx18 9 minutes ago

Take note of this DD: 👉️ HIV patients 👈️
I look forward to working with the team to develop novel therapeutics that can significantly improve the lives of HIV patients. $CBDW

https://www.otcmarkets.com/stock/CBDW/news/story?e&id=3051450

CBDW

chemist72 9 minutes ago

Won't stick my neck out that far to predict when GDVM might close above a penny.

But I've been around OTC long enough to know that almost anything is possible in this market.

But I agree with you that just one "whiff" of good news and GDVM will go above $.01 easily.

GDVM

getmoreshares 9 minutes ago

Outstanding Shares
4,486,579,772
11/25/2024
Restricted
297,032,738
11/25/2024
Unrestricted
4,189,547,034
11/25/2024
Held at DTC
4,189,371,869
11/25/2024

DTC

glenn1919 9 minutes ago

kdly........tpet........nuwe.....ivda......................https://stockcharts.com/h-sc/ui?s=IVDA&p=D&yr=0&mn=2&dy=12&id=p84071410134

IVDA

chrismiss_everyday 9 minutes ago

Give Shkreli some more years in the joint to meditate on his inner void.

https://www.justice.gov/usao-edny/pr/martin-shkreli-sentenced-seven-years-imprisonment-multi-million-dollar-fraud-scheme

AVXL

Doubledown75 10 minutes ago

Reminds me of the movie "office space", guy had enough and just wanted his stalper back I guess lol.
Let's lose a zero for turkey day!!!

BLEG

phytokaiser1 10 minutes ago

Timestamp?

What I have heard is he said it's super interesting, tons of errors and that they are making a lot of it up as they go along.

IMO, the publication needs to be super clean and concise with no errors.

I am still long this stock

AVXL

	Real-time Prices	Level 2
Dow Jones Indices
Toronto Stock Exchange
Toronto Stock Exchange Venture Exchange
OTCBB
New York Stock Exchange
NASDAQ
American Stock Exchange
OTCMarkets
Canadian Securities Exchange
OPRA
OPRA Indices
Forex

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Genmab AS (GE9)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

About Genmab AS

Ask ADVFN Intelligence (AI)

GE9 Latest News

Genmab to Present at Citi’s Global Healthcare Conference

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Genmab Announces Financial Results for the First Nine Months of 2024

Genmab to Present at Jefferies London Healthcare Conference

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024

Major Shareholder Announcement

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Movers

Discussion

Your Recent History

Company

Business

Popular

Get The App

BLACK FRIDAY

Save up to 60%* for North American Extreme

1 year 40%, 2 years 40% and *3 years 60%

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Genmab AS (GE9) Share Price

Genmab AS (GE9)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

About Genmab AS

Ask ADVFN Intelligence (AI)

GE9 Latest News

Movers

Discussion

Your Recent History

Company

Business

Popular

Get The App

BLACK FRIDAY

Save up to 60%* for Canadian Securities Exchange (CSE) Level 1 and 2

1 year 40%, 2 years 40% and *3 years 60%